Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$0.18
EPS est.
$0.06
EPS surprise
+200.00%
1-day move
+6.01%
Acadia Pharmaceuticals reported a positive surprise in EPS, which contributed to a 6.01% increase in stock price. However, there was no revenue reported or guidance provided, leaving investors with limited insights into future performance. The strong EPS result indicates better-than-expected profitability for the quarter.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.18 | N/A | +200.00% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.
ACADIA Pharmaceuticals Inc. is a biotechnology company focused on developing innovative treatments for central nervous system disorders. With a market cap of $5 billion, it plays a crucial role in the healthcare sector, particularly in addressing unmet medical needs in mental health and neurological conditions.
Last quarter
In Q1 2026, ACADIA reported an EPS of $0.02, which was significantly below the expected $0.04, leading to a stock decline of 3.89% the next day. The company continues to face challenges in meeting analyst expectations.
EPS beat streak
1Q
EPS beat rate
88%
Avg EPS surprise
+248.44%
Avg 1-day reaction
+1.70%
Overall, expectations are mixed as ACADIA has a strong track record of beating EPS estimates, but recent performance raises concerns about future growth.
Bull case
If ACADIA can deliver strong revenue growth and maintain or improve its EPS, it could signal a recovery and renewed investor confidence.
Bear case
Conversely, if the company continues to miss expectations, especially in revenue, it may lead to further declines in stock price and investor sentiment.
The print will turn on these.
Q1
What will the EPS be for Q2 2026, and how does it compare to analyst expectations?
Given the company's recent struggles to meet EPS estimates, this number will be critical in determining investor confidence.
Q2
What is the revenue growth rate for this quarter?
Revenue growth is vital for assessing the company's market performance and future prospects, especially after a disappointing last quarter.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be underestimating the potential for a rebound in ACADIA's performance, especially given its historical ability to beat EPS estimates.
Supporting evidence
The company has an 88% EPS beat rate historically, suggesting it often exceeds expectations.
Despite recent misses, the stock has shown resilience in past quarters, often recovering after initial declines.
Key risk
If the EPS comes in significantly above $0.02, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is crucial as it follows a significant miss in the previous quarter, and investors are looking for signs of recovery.
Bull confirmed if
A revenue growth rate of over 15% would confirm the bull case and indicate strong market acceptance of ACADIA's products.
Bear confirmed if
A revenue decline or stagnation would confirm the bear case, raising concerns about the company's future viability.
What the market is pricing for the move.
Implied Move
±10.63%
Historical Avg
±2.7%
The options market is pricing in a significant potential move in either direction, indicating uncertainty among investors.
Options are pricing ±10.6% while ACAD has averaged ±2.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
33.8%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
99.68%
of float
Insider
0.33%
of float
Holders
474
institutions
Top Holders· as of Jun 2026
Baker Bros. Advisors, LP
42,912,904 sh · $843.2M
24.91%
0.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If ACADIA beats expectations, history suggests the stock could rise by about 1.98%, confirming a positive turnaround.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
A miss could lead to a decline of around 3.89%, reflecting ongoing concerns about the company's growth trajectory.
The lines on the call that would change the story.
Blackrock Inc.
22,515,173 sh · $442.4M
13.07%
4.5%
State Street Corporation
9,076,212 sh · $178.3M
5.27%
8.9%
Vanguard Portfolio Management LLC
8,838,450 sh · $173.7M
5.13%
1.9%
RTW Investments LP
7,144,524 sh · $140.4M
4.15%
Flat
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.